NCT00334984撤回不适用
Prevention of Mucositis in Children With AES-14 (IND#36978), a Glutamine Based Oral Care Regimen, for Patients Diagnosed With Solid Tumors: A Randomized Placebo-Controlled Clinical Study
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 撤回
研究概览
简要总结
RATIONALE: Glutamine may help prevent mucositis, or mouth sores, in patients receiving chemotherapy for sarcoma. It is not yet known whether glutamine is more effective than a placebo in preventing mucositis in patients receiving chemotherapy for sarcoma.
PURPOSE: This randomized clinical trial is studying glutamine to see how well it works compared to a placebo in preventing oral mucositis in patients receiving chemotherapy for sarcoma.
详细描述
OBJECTIVES:
Primary
- Compare the efficacy of a new preparation of glutamine (AES-14) vs placebo in reducing the incidence of grade 3 or 4 chemotherapy-induced oral mucositis during the first course of chemotherapy in patients with sarcomas.
Secondary
- Compare the rates of mucositis-related chemotherapy dose reductions for the subsequent course of anthracycline-based chemotherapy in patients treated with AES-14 vs placebo.
- Compare the rates of mucositis-related delays of chemotherapy administration for the next chemotherapy course in patients treated with AES-14 vs placebo.
- Compare the rates of systemic and oral infections during the first course of chemotherapy in patients treated with AES-14 vs placebo.
- Compare the number of days of narcotic use for mucositis-related pain during the first course of chemotherapy in patients treated with AES-14 vs placebo.
- Determine the inter-rater reliability between caregivers and nurses in the use of the modified Walsh scale.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 主要目的
- Supportive Care
- 盲法
- Double
入排标准
- 年龄范围
- 5 Years 至 30 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •DISEASE CHARACTERISTICS:
- •Diagnosed with any of the following:
- •Ewing's sarcoma
- •Osteogenic sarcoma
- •Rhabdomyosarcoma
- •Other sarcomas (i.e., fibrosarcoma or synovial sarcoma)
- •Scheduled to receive first course of chemotherapy that includes ≥ 75 mg/m² of anthracyclines
- •Total modified Walsh score ≤ 2 (mucositis score)
- •PATIENT CHARACTERISTICS:
- •Must have a caregiver (parent, other relative, or friend) available to perform daily mucositis assessments
- •Bilirubin ≤ 1.5 times upper limit of normal (ULN)
- •ALT ≤ 5 times ULN
- •Albumin ≥ 2 g/dL
- •No history of hypersensitivity to any known component of AES-14
- •PRIOR CONCURRENT THERAPY:
- •No prior glutamine (AES-14)
- •No prior or concurrent head and/or neck radiation therapy
- •No concurrent supplementation with another glutamine product
- •No other concurrent agents for mucositis prophylaxis
排除标准
- 未提供
研究者
相似试验
已完成
不适用
Prevention of Oral Mucositis Using Photobiomodulation TherapyOral MucositisNCT04227340St. Jude Children's Research Hospital43
招募中
4 期
Prevention of oral mucositis in pediatric patients with acute lymphoblastic leukemia undergoing chemotherapy: a randomized controlled, cross-over trial using 0.12% chlorhexidine gluconate and 1% povidone iodine mouthwashoral mucositisCancer - Children's - Leukaemia & LymphomaOral and Gastrointestinal - Inflammatory bowel diseaseleukemiaACTRN12614000158662Amanda Christina C. Dujua, MD20
已完成
2 期
Prevention of the chemotherapy-induced oral mucositis by the rebamipide in breast cancer patients (Phase II)Oral mucositisJPRN-UMIN000005712Cinderella Study Group160
已完成
2 期
Glutamine in Treating Side Effects in Children Who Are Undergoing Stem Cell TransplantationOral ComplicationsUnspecified Childhood Solid Tumor, Protocol SpecificNCT00003898Roswell Park Cancer Institute120
撤回
3 期
Ketamine and Hydromorphone for Patient Controlled Pain Relief in Children's MucositisMucositisNCT00474110University of British Columbia